Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: The PrEP Registry



Iron deficiency (ID) and anaemia are common in heart failure (HF). The prospective, observational PReP registry (Prävalenz des Eisenmangels bei Patienten mit Herzinsuffizienz) studied prevalence and clinical impact of ID and anaemia in HF outpatients attending cardiology practices in Germany.

Methods and results

A total of 42 practices enrolled consecutive patients with chronic HF [left ventricular ejection fraction (LVEF) ≤45%]. ID was defined as serum ferritin <100 µg/l, or serum ferritin ≥100 µg/l/<300 µg/l plus transferrin saturation <20%, and anaemia as haemoglobin <13 g/dl (12 g/dl) in men (women). Exercise capacity was assessed using spiroergometry (69.4%) or 6-min walk test (30.4%). Amongst 1198 PReP-participants [69.0  ± 10.6 years, 25.3% female, New York Heart Association (NYHA) class 2.4  ± 0.5, LVEF 35.3 ± 7.2%], ID was found in 42.5% (previously unknown in all), and anaemia in 18.9% (previously known in 4.8%). ID was associated with female gender, lower body weight and haemoglobin, higher NYHA class and natriuretic peptide (NP) levels (all p < 0.05). ID was also more common in anaemic than non-anaemic patients (p < 0.0001), and 9.8% of PrEP-participants had both, ID and anaemia. On spiroergometry, ID independently predicted maximum exercise capacity even after multivariable adjustment, including anaemia (p = 0.0004). In all PrEP-participants, ID predicted reduced physical performance (adjusted for age, gender, anaemia, serum creatinine, C-reactive protein, LVEF, and NP level).


Despite high prevalence, ID was previously unknown in all PrEP-participants, and anaemia was often unappreciated. Given the clinical relevance, treatability, and independent association with reduced physical performance, ID should be considered more in real-world ambulatory healthcare settings and ID-screening be advocated to cardiologists in such populations.


Besides anaemia, iron deficiency (ID) has more recently been recognized as a separate clinically relevant co-morbidity in patients with heart failure (HF) and other cardiovascular illnesses, with serious consequences for patient well-being and outcomes [1, 2]. The pivotal importance of iron is based on its essential role in oxygen transport, and its central role in processes maintaining cellular energy in high-energy demanding tissues like cardiac muscle [35].

ID can be classified into absolute ID, reflecting depleted iron stores, and functional ID, where iron delivery to target cells is hampered despite normal or overly abundant iron stores [6]. In healthy subjects, ID is generally diagnosed using a serum ferritin cut-off level <30 µg/l for absolute ID [7]. Because ferritin is also an acute phase reactant, pro-inflammatory activity increases its synthesis, thus rendering the diagnosis of ID more difficult in diseases associated with chronic subclinical inflammation. A ferritin cut-off value <100 µg/l is currently considered diagnostic for ID in patients with HF irrespective of transferrin saturation (TSAT). Alternatively, a cut-off value <300 µg/l together with a TSAT <20% may be used [8, 9]. Reduced TSAT is viewed as an indicator of insufficient iron availability for metabolizing cells [10].

Dependent on the various ID definitions, the prevalence of ID has been estimated between 13 and 34% with higher incidence rates among anaemic patients [11, 12]. Using the above diagnostic criteria, Jankowska et al. recently documented a 37% prevalence of ID among 546 patients with chronic systolic HF [13] and identified female gender, advanced disease (New York Heart Association class, and elevated plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) and serum high-sensitivity C-reactive protein levels as independent predictors of a higher likelihood of ID in a relatively young and predominantly male HF population. Little is known about the prevalence and clinical impact of ID with or without concurrent anaemia in a clinically stable, community-dwelling outpatient population with chronic HF. The prospective observational PReP registry (Prävalenz des Eisenmangels bei Patienten mit Herzinsuffizienz) was created to study prevalence and clinical impact of ID and anaemia in a real-world setting of ambulatory patients with HF.


Between November 2010 and March 2012, ambulatory patients with chronic HF who presented at one of 42 office-based cardiologist practices in Germany were recruited into the prospective PrEP registry. All male and female patients aged 18 years and older were eligible, provided a left ventricular ejection fraction of 45% or less was documented on echocardiography during the enrolment visit and signs and symptoms of chronic heart failure were present. All patients gave written informed consent to the analysis of their pseudonymized clinical and laboratory data as part of the PReP registry. Practices were asked to include patients consecutively. None of the participating cardiologists reported any patients who a priori declined participation. However, the study protocol did not foresee entry of all screened patients into a screening and enrolment log sheet. Exclusion criteria were coronary interventions of any kind within the past 6 months and planned coronary interventions, evidence of acute or chronic infectious or inflammatory conditions from routine laboratory assessment, malignant disease or gastric or duodenal ulcer with or without active bleeding, and lack of written informed consent. The ethics committee of the Bavarian Chamber of Physicians, Munich, Germany, approved the study, and all patients provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki.

A total of 1602 patients with chronic symptomatic HF were enrolled. Four hundred and four of these participants had to be excluded from the final data set and subsequent analysis due to protocol violations (particularly in one centre whose entire patient cohort had to be excluded because of insufficient or ambiguous data documentation) or because essential data were missing. Patient baseline assessment included a standardized HF history regarding HF aetiology (classified as ischaemic or non-ischaemic) and co-morbidities.

All patients underwent a standardized clinical evaluation, including physical examination, determination of NYHA class, determination of body weight, and determination of the heart rate from the electrocardiogram and of blood pressure by the Riva-Rocci method. In addition, patients underwent semiquantitative assessment of their volume status, in which peripheral oedema was classified as absent, mild, or significant. Blood samples were drawn from an antecubital vein in the morning for the assessment of a full blood count and clinical chemistry, including parameters of iron metabolism [serum ferritin, transferrin, and transferrin saturation (TSAT)] and kidney function (creatinine).

Renal dysfunction was diagnosed if the glomerular filtration rate was below 60 ml/min/1.73 m2, diabetes mellitus, if patients reported a history of diabetes or were on anti-diabetic drugs, and chronic obstructive pulmonary disease (COPD), if patients were on anti-obstructive pharmacotherapy or reported that COPD had been previously diagnosed. A history of depression was assumed if patients reported a previous respective physician diagnosis or were undergoing any specific antidepressant therapy. The diagnosis of restless legs was documented if patients reported that this condition had been previously diagnosed. Anaemia was defined according to World Health Organization criteria as haemoglobin level <12 g/dl in women and <13 g/dl in men [14]. ID was defined as serum ferritin <100 µg/l, or serum ferritin ≥100 µg/l and <300 µg/l with TSAT <20%. For natriuretic peptide assessment, either determination of B-type natriuretic peptide (BNP) or N-terminal-proBNP (NT-proBNP) was permitted according to local standards. Assessment of exercise capacity was performed either by spiroergometry testing or a 6-min corridor walk test, depending on local circumstances and availability. Exercise capacitly was categorized as reduced, if patients performed below the median of the respective test, i.e., below the median exercise capacity at spiroergometry or below the median walking distancene during the 6-min walk test, respectively.

Statistical analyses

Continuous variables are given as means with standard deviations. Non-normally distributed variables (serum ferritin, serum creatinine, serum C-reactive protein, and natriuretic peptides) were log-transformed to achieve normal distribution before analysis. Student’s t test and analysis of variance (ANOVA) with Fisher’s post-hoc test were used to test for between-group differences. Categorical variables were expressed as numbers with percentages and the Chi-square test was used to test for inter-group proportion differences. Simple regression was used to analyse the first-line associations between continuous variables.

Univariate and multivariate logistic regression models were used to identify clinical determinants of exercise capacity in patients with chronic HF. The analyses included continuous and dichotomized variables of the parameters age, gender, NYHA class, LVEF, natriuretic peptide levels, the presence of anaemia, and the presence of ID. All statistical analyses were performed using StatView version 5.0 for Mac (Abacus Concepts, Berkeley, California). All tests were two-sided. P values of <0.05 were considered statistically significant.


The final data set comprised 1198 patients, 25.7% of whom were female. Baseline characteristics are given in Table 1. Patients were elderly, with a mean age of 69.0  ± 10.6 years. HF aetiology was predominantly ischaemic (62.4%). The NYHA distribution was n = 730 (60.9%) for NYHA class II, n = 457 (38.1%) for class III, and n = 11 (0.01%) for class IV. HF medications included angiotensin-converting enzyme inhibitors (68.6%), angiotensin receptor blockers (24.6%), beta-blockers (86.1%), mineralocorticoid receptor antagonists (39.1%), and digitalis (18.4%). A total of 87.9% of all patients received either an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, and 64 patients (5.3%) received both. Diuretics were prescribed in 76.3% of the patients. A total of 864 patients (69.6%) underwent spiroergometry and the remaining 334 patients (30.4%) completed a 6-min walk test.

Table 1 Baseline characteristics of the total study population and of patients with versus without iron deficiency

Prevalence of iron deficiency

ID was present in 509 (42.5%) of the PrEP-participants and not previously known in any of them. None of the patients had a history of iron supplementation of any kind. Compared with PrEP-participants without ID, these patients had lower body weight (p = 0.01), haemoglobin levels (<0.0001) and mean corpuscular haemoglobin volume (p < 0.0001), and higher platelet count (p < 0.0001), NYHA class (p = 0.0003), and B-type natriuretic peptide (BNP) (p = 0.01) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) values (p = 0.0015, Table 1). By contrast, no differences were recorded for age, resting heart rate, blood pressure, LVEF, leukocyte count, C-reactive protein, or serum creatinine (all p > 0.05).

Among patients who reported to suffer from restless legs syndrome and those with a history of depression, ID was significantly more prevalent than in the group without ID (Table 1, p = 0.03 and p = 0.002, respectively). No such differences were found regarding hypertension, diabetes, renal dysfunction, or chronic obstructive pulmonary disease.

Prevalence of anaemia

Two hundred and twenty six (18.9%) of the PrEP-participants presented with anaemia. Despite high prevalence, this co-morbidity was known prior to enrolment only in 4.8%. None of the patients had received erythropoietin or blood transfusion for the treatment of anaemia. Anaemic patients were more likely to have concomitant ID than non-anaemic patients (p = 0.02), and anaemia and ID were concomitantly present in 117 (9.8%) of the patients.

Baseline haemoglobin strongly correlated with serum ferritin (r = 0.16, p < 0.0001), TSAT (r = 0.26, p < 0.0001), C-reactive protein (r = −0.15, p < 0.0001), and serum creatinine (r = −0.14, p < 0.0001). When analysed separately, there was a highly significant association between haemoglobin and serum ferritin in patients with ID (r = 0.16, p = 0.0004), whereas in patients without ID, this association was only of borderline significance (r = −0.09, p = 0.03). No corresponding associations were noted between haemoglobin and TSAT, C-reactive protein, or serum creatine after splitting the data set into patients with vs. without ID. In univariable analysis, the presence of anaemia, ID, or both was associated with significantly higher NYHA class (Figs. 1 and 2).

Fig. 1

NYHA class according to baseline status being iron-deficient, anaemic, both or none of the two. ANOVA p < 0.0001

Fig. 2

NYHA class according to baseline status being iron-deficient, anaemic, both or none of the two, devided by gender. Male blue bars, female red bars. Number above the bars represents n numbers in each group

Predictors of exercise capacity

Maximum exercise capacity as assessed by spiroergometry was significantly lower in patients with ID (p = 0.0004), while regarding the 6-min walking distance, there was no significant difference in patients with versus without ID (p = 0.24). Using logistic regression, we found that age, gender, body weight, systolic and diastolic blood pressure, NYHA class, the presence of oedema, LVEF, the presence of anaemia, haemoglobin, the presence of ID, serum ferritin, transferrin saturation (TSAT), serum creatinine, a history of chronic kidney disease, and a history of anaemia all predicted lower exercise capacity (all p < 0.05, Table 2). The same was true for BNP or NT-proBNP values above the diagnostic cut-off for non-acute HF (>35 pg/ml and >125 pg/ml, respectively). After adjustment for age, gender, the presence of anaemia, creatinine, LVEF, and natriuretic peptide levels, the presence of ID remained an independent predictor of reduced exercise capacity [odds ratio (OR) 1.323, 95% confidence interval (CI) 1.009–1.735, p = 0.04]. Likewise, the presence of anaemia independently predicted reduced exercise capacity after adjusting for age, gender, creatinine, CRP, LVEF, the presence of ID, and natriuretic peptide levels (OR 1.939, 95% CI 1.356–2.773, p = 0.0003).

Table 2 Univariable and multivariable logistic regression models to predict baseline exercise capacity among 1198 patients with HF with reduced ejection fraction


To our knowledge, the PReP Registry constitutes so far the largest prospective cohort study in ambulatory patients with chronic stable systolic HF evaluating the prevalence and clinical impact of ID and anaemia in a real-world healthcare setting. With 42.5%, ID proved highly prevalent in this population of outpatients taken care of in office-based cardiology practices across Germany. With 18.9% the proportion of anaemia was significantly lower than that of ID. Interestingly, the overlap between the two populations was smaller than one might have expected, since only every second anaemic patient also presented with ID at the same time. Independent of the presence of anaemia, ID predicted lower physical performance irrespective of the exercise test used, i.e., a walking distance or maximum exercise capacity on spiroergometry below the median, which highlights the functional importance of this co-morbidity for the patients. Likewise, the presence of anaemia also predicted a significantly lower maximum exercise capacity.

Prevalence and possible consequences of iron deficiency

Prevalence and possible consequences of ID complicating HF have more recently been attracting increasing attention. Many (mostly secondary) analyses were published that addressed the prevalence of ID in HF cohorts often derived from other clinical studies [13, 1517]. In this context, Opasich et al. demonstrated, e.g., that the majority of patients with chronic HF and low haemoglobin levels had anaemia of chronic disease, and nearly, all had deficient iron supply for erythropoiesis and/or blunted endogenous erythropoietin production [15]. Among more than 500 ambulatory patients with stable HF, Jankowska et al. found an ID rate of 32 and 57% in anaemic and non-anaemic subjects, respectively [13]. Schou et al. using the same cut-off criteria as Jankowska et al. to define ID, found among Danish outpatients with characteristics similar to those of the PrEP-participants (25% female, NYHA III-IV, mean LVEF 32%) an ID prevalence of 45% and thus very comparable to our findings [17]. Our findings from the PrEP registry regarding ID prevalence are thus in accordance with published data from several clinical cohorts as well as from smaller outpatient cohorts. The PrEP results also correspond to a recent report from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF): [18]. Among outpatients with systolic HF, 30% presented with anaemia and 45% with ID. Remarkably, and also in line with our observations, exercise capacity decreased in parallel to decreasing haemoglobin levels (r = 0.24, p < 0.001) in SICA-HF. Furthermore, exercise capacity proved significantly lower in 19% of the patients who presented with both, anaemia and ID, compared with those with either ID or anaemia, respectively.

Even though the prevalence of restless legs syndrome or a history of depression was low, the proportion of ID among affected PrEP-participants was significantly higher than among patients without ID. This finding is in line with the previous observations by Allen et al., who found a 23.9% prevalence of this syndrome among 251 first-presenters with ID and anaemia and no treatment for restless legs syndrome [19]. A similar association was previously also suggested for depression [20]. In conjunction with the previous findings, our present results indicate the possibility of adverse neuro-psychiatric effects of ID as yet another intriguing facet of its complex systemic sequels. However, prospective research needs to ascertain these interrelations, since our observation of a higher prevalence of patient-reported restless leg syndrome or a history of depression in patients with ID does not establish causality, as it is subject to various kinds of bias. In particular, future studies need to employ appropriate validated tools to evaluate and quantify both conditions at the time of study enrolment rather than rely on patients’ history.

Therapeutic options in iron deficiency and anaemia

Common clinical practice treatment options of anaemia in patients with HF, which might be considered after exclusion of treatable/reversible causes (e.g., gastrointestinal bleeding), include application of erythropoietin and its derivatives, blood transfusions, or iron administration. However, the Reduction of Events in Heart Failure trial (RED-HF) using darbepoetin-alfa in anaemic patients with HF recently ended neutral, [21] and blood transfusions should be restricted to selected symptomatic patients with very low haemoglobin levels, predominantly those <8 g/dl, leaving repletion of iron stores as the only promising treatment option with anaemia and ID that may be applied routinely in clinical practice. Our findings of a high prevalence of ID not always coincide with anaemia among PrEP-participants and the independent association of ID with reduced exercise capacity in our cohort buttress applicability of the current guideline recommendation regarding repletion of ID also in the outpatient setting. They suggest that iron substitution should be considered in symptomatic outpatients with chronic stable HF with reduced ejection fraction and ID and anaemia, but also, if there is no concomitant anaemia [2].

Using the same definition of ID as employed in the PrEP registry, the Ferinject Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) trial randomized patients with symptomatic HF and a LVEF ≤40% (or ≤45% and NYHA III) with ID and haemoglobin levels between 9.5 and 13.5 g/dl to intravenous ferric carboxymaltose or saline [22]. After 24 weeks, self-reported patient global assessment had improved significantly more often in patients receiving ferric carboximaltose (50% vs 28%, p < 0.001), and various secondary endpoints, including NYHA class and quality of life, had also improved [23]. Using a similar study design, the ferric CarboxymaltOse evaluatioN on perFormance in patients with IRon deficiency in coMbination with chronic Heart Failure (CONFIRM-HF) study extended these findings in an outpatient population with ID and similar characteristics to an observation period of 52 weeks [24]. Importantly, hospital admissions for worsening HF, which constituted a pre-defined secondary endpoint, were significantly reduced in CONFIRM-HF. The Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure (EFFECT-HF) trial, even though open label, further extended these findings by showing that intravenous iron therapy with ferric carboxymaltose improves exercise capacity as assessed using spiroergometry [25]. A recent meta-analysis involving five trials, which evaluated intravenous iron therapy in iron-deficient patients with systolic heart failure, confirmed that this treatment improves clinical outcomes, exercise capacity, and quality of life, and to alleviate HF symptoms [26]. In line with these results, another meta-analysis showed that iron supplementation reduced the need for blood transfusions and increased haemoglobin levels in patients with chronic kidney disease or in the peri-partal period [27]. The recently published Oral Iron Repletion effects ON Oxygen UpTake in Heart Failure (IRONOUT) trial has underscored missing benefit of oral iron therapy, as no increase in exercise capacity and only a minimal increase in serum ferritin level were noted after 12 weeks of therapy [28].

Against this background, current guidelines for the management of HF advocate the repletion of ID with the inclusion criteria of FAIR-HF as defining features for patients eligible for treatment [2]. In addition, the guidelines state that blood biochemistry parameters should be regularly assessed to “detect reversible/treatable causes of HF (e.g., hypocalcaemia, thyroid dysfunction) and co-morbidities (e.g., iron deficiency)”. With regard to anaemia, the guidelines list “chronic HF, haemodilution, iron loss or poor utilization, renal failure, chronic disease, (and) malignancy” as potential reasons for anaemia development, and recommend to perform a “diagnostic work-up” and to “consider treatment” [2]. A recent French position paper states that iron supplementation should be considered “for all patients with chronic HF or hospitalized for acute decompensation of chronic HF with biological evidence of iron insufficiency” [29].


Findings of this study should be interpreted in the light of its limitations. First, the PrEP registry derived all study data from informations obtained during routine patient care. Patient phaenotyping was, therefore, not strictly standardized and performed according to local circumstances, which precluded, e.g., the use of uniform exercise testing or determination of just one natriuretic peptide. The diagnosis of co-morbidities as restless leg syndrome, depression, diabetes, or COPD was based on patients’ reports and not ascertained in the frame of the study. Moreover, cardiologists were asked to recruit patients consecutively, but did not complete a screening and enrolment log. Although they did not report any patients denying participation, patient selection may have been biased by factors unaccounted for in this study. Finally, PrEP-participants were recruited between 2010 and 2012, when in general, diagnosis and management of co-morbidities received less attention than recommended in the most recent version of the European Society of Cardiology HF guidelines. Awareness of anaemia and ID as common characteristics of the HF syndrome with adverse impact on prognosis may since have increased also amongst physicians responsible for HF outpatient care. However, the PrEP registry results, derived from the so far largest stable outpatient cohort of symptomatic HF patients, provide for the first time strong arguments to diagnose and treat these conditions also in stable outpatients attending cardiologist practices, and appear suited to call cardiologists into responsibility in this respect. PrEP results may thus significantly reinforce routine assessment of iron status and help to establish iron supplementation as a treatment option also in current ambulatory HF care.


The PReP registry, which involved a large cohort of patients with symptomatisc systolic HF enrolled in 42 German office-based cardiology practices, demonstrated high prevalence of both anaemia and ID (18.9% and 42.5%, respectively) in this population. Despite this high prevalence, anaemia was often unappreciated, and ID was previously unknown in all PrEP-participants. Clinical relevance, treatability, and independent association with reduced physical performance as demonstrated by the PrEP results call for routine diagnostic clarification of anaemia and ID-screening in ambulatory healthcare settings to further improve current outpatient HF care.


  1. 1.

    von Haehling S, Jankowska EA, van Veldhuisen DJ, Ponikowski P, Anker SD (2015) Iron deficiency and cardiovascular disease. Nat Rev Cardiol 12:659–669

    Article  Google Scholar 

  2. 2.

    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P on behalt of the Authors/Task Force Members and Document Reviewers (2016) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail 18:891–975

    Article  PubMed  Google Scholar 

  3. 3.

    Andrews NC (1999) Disorders of iron metabolism. N Engl J Med 341:1986–1995

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 2001;131(Suppl 2):568S–579S

  5. 5.

    Turer AT, Malloy CR, Newgard CB, Podgoreanu MV (2010) Energetics and metabolism in the failing heart: important but poorly understood. Curr Opin Clin Nutr Metab Care 13:458–465

    Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Wish JB (2006) Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 1(Suppl 1):S4–S8

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Pasricha SR, Flecknoe-Brown SC, Allen KJ, Gibson PR, McMahon LP, Olynyk JK, Roger SD, Savoia HF, Tampi R, Thomson AR, Wood EM, Robinson KL (2010) Diagnosis and management of iron deficiency anaemia: a clinical update. Med J Aust 193:525–532

    PubMed  Google Scholar 

  8. 8.

    Glaspy J, Cavill I (1999) Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Int Soc Cell 13:461–473

    CAS  Google Scholar 

  9. 9.

    Ebner N, von Haehling S (2013) Iron deficiency in heart failure: a practical guide. Nutrients 5:3730–3739

    Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P, for the FAIR-HF Trial Investigators (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361:2436–2448

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Ezekowitz JA, McAlister FA, Armstrong PW (2003) Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 107:223–225

    Article  PubMed  Google Scholar 

  12. 12.

    Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, Tsagalou EP, Maroulidis GD, Alexopoulos GP, Kanakakis JE, Anastasiou-Nana MI (2006) Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 48:2485–2489

    Article  PubMed  Google Scholar 

  13. 13.

    Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P (2010) Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 31:1872–1880

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Blanc B, Finch CA, Hallberg L, Nutritional anaemias (1968) Report of a WHO scientific group. WHO Tech Rep Ser 405:1–40

    Google Scholar 

  15. 15.

    Opasich C, Cazzola M, Scelsi L, DeFeo S, Bosimini E, Lagioia R, Febo O, Ferrari R, Fucilli A, Moratti R, Tramarin R, Tavazzi L (2005) Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 26:2232–2237

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Adlbrecht C, Kommata S, Hu¨lsmann M, Szekeres T, Bieglmayer C, Strunk G, Karanikas G, Berger R, Mortl D, Kletter K, Maurer G, Lang IM, Pacher R (2008) Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body’s red cell volume. Eur Heart J 29:2343–2350

    Article  PubMed  Google Scholar 

  17. 17.

    Schou M, Bosselmann H, Gaborit F, Iversen K, Goetze JP, Soletomas G, Rasmussen J, Kistorp C, Kober L, Gustafsson F, Tonder N (2015) Iron deficiency: prevalence and relation to cardiovascular biomarkers in heart failure outpatients. Int J Cardiol 195:143–148

    Article  PubMed  Google Scholar 

  18. 18.

    Ebner N, Jankowska EA, Ponikowski P, Lainscak M, Elsner S, Sliziuk V, Steinbeck L, Kube J, Bekfani T, Scherbakov N, Valentova M, Sandek A, Doehner W, Springer J, Anker SD, von Haehling S (2016) The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the studies investigating co-morbidities aggravating heart failure. Int J Cardiol 205:6–12

    Article  PubMed  Google Scholar 

  19. 19.

    Allen RP, Auerbach S, Bahrain H, Auerbach M, Earley CJ (2013) The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. Am J Hematol 88:261–264

    Article  PubMed  Google Scholar 

  20. 20.

    Pamuk GE, Top MŞ, Uyanık MŞ, Köker H, Akker M, Ak R, Yürekli ÖA, Çelik Y (2016) Is iron-deficiency anemia associated with migraine? Is there a role for anxiety and depression? Wien Klin Wochenschr 128(Suppl 8):576–580

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Swedberg K, Young JB, Anand IS, Cehng S, Desai AS, Diaz R, Maggioni AP, MvMurray JJ, O’Connor,C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ, RED-HF Committees, RED- HF Investigators (2013) Treatment fo anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368:1210–1219

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Mori C, von Eisenhart Rothe B, Pocock S, Poole-Wilson PA, Ponikowski P; FAIR-HF committees and investigators (2009) Rationale and design of ferinject assessment in patients with iron deficiency and chronic heart failure (Fair-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 11:1084–1091

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361:2436–2448

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh TA, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD (2014) Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC Heart Failure 1:52–58

    Article  Google Scholar 

  25. 25.

    van Veldhuisen DJ, Ponikowski P, Metra M, Böhm M, van der Meer P, Doletsky A, Voors AA, Macdougall IC, Roubert B, Anker SD, Cohen Solal A. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure (EFFECT-HF): A Randomized, Controlled Study.!/4096/presentation/58426. Accessed 21 Nov 2016

  26. 26.

    Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W, Banasiak W, Filippatos G, Anker SD, Ponikowski P (2016) Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail 18:786–795

    CAS  Article  PubMed  Google Scholar 

  27. 27.

    Clevenger B, Gurusamy K, Klein AA, Murphy GJ, Anker SD, Richards T (2016) Systematic review and meta-analysis of iron therapy in anaemic adults without chronic kidney disease: updated and abridged Cochrane review. Eur J Heart Fail 18:774–785

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Lewis GD, Anstrom KJ, McNulty S, Hernandez AF, Braunwald E, for the NHLBI Heart Failure Network (2016) Oral iron repletion effects on oxygen uptake in heart failure (IRONOUT HF).!/4096/presentation/58425. Accessed 21 Nov 2016

  29. 29.

    Cohen-Solal A, Leclercq C, Mebazaa A, De Groote P, Damy T, Isnard R, Galinier M (2014) Diagnosis and treatment of iron deficiency in patients with heart failure: expert position paper from French cardiologists. Arch Cardiovasc Dis 107:563–571

    Article  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Stephan von Haehling.

Ethics declarations


This work was supported by Vifor Pharma.

Conflict of interest

SvH has received consulting honoraria from Vifor Pharma and lecture fees from Amgen. C.E. Angermann acknowledges grant and other support, speaker honoraria, and consultancy fees from Vifor Pharma. All other authors have no conflicts of interest relevant to this manuscript to disclose.

Additional information

Johannes B. Dahm and Christiane E. Angermann authors have contributed equally.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

von Haehling, S., Gremmler, U., Krumm, M. et al. Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: The PrEP Registry. Clin Res Cardiol 106, 436–443 (2017).

Download citation


  • Iron deficiency
  • Anaemia
  • Exercise capacity
  • Heart failure
  • Prevalence